CJC-1295

Reliably raises GH and IGF-1 in human studies. Not FDA-approved; widely used off-label in anti-aging clinics.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Multiple human pharmacokinetic studies confirm sustained GH elevation. Limited long-term safety data. Typically refers to the version without DAC (Drug Affinity Complex).

• Sustained increase in GH and IGF-1 levels
• Pulsatile GH release pattern preserved
• Used in combination with GH secretagogues in clinical protocols

Typical clinic protocols: 100–300 mcg subcutaneously at bedtime. Often combined with ipamorelin.

• Flushing
• Headache
• Water retention
• Injection-site reactions
• Transient numbness or tingling

Not FDA-approved. Long-term effects of chronic GH elevation are a concern. Avoid in individuals with active malignancies.

GH-axis stimulation is confirmed but clinical outcome data (body composition, aging) are limited.

• Muscle40
• Recovery35
• Longevity25